➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Johnson and Johnson
McKinsey
AstraZeneca
Merck

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 10,478,497

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,478,497
Title:Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
Inventor(s): Benjamin; Susan (Chatillon, FR), Planquette; Cecile (Palaiseau, FR), Delansorne; Remi (Paris, FR)
Assignee: HYBRIGENICS S.A. (Paris, FR)
Application Number:15/655,394
Patent Claims:see list of patent claims

Details for Patent 10,478,497

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial HYBRIGENICS S.A. (Paris, FR) 2039-12-05 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 002 2015-11-16   Start Trial HYBRIGENICS S.A. (Paris, FR) 2039-12-05 RX Orphan search
Sanofi Aventis Us SARCLISA isatuximab-irfc INJECTABLE;INJECTION 761113 001 2020-03-02   Start Trial HYBRIGENICS S.A. (Paris, FR) 2039-12-05 RX Orphan search
Sanofi Aventis Us SARCLISA isatuximab-irfc INJECTABLE;INJECTION 761113 002 2020-03-02   Start Trial HYBRIGENICS S.A. (Paris, FR) 2039-12-05 RX Orphan search
Sanof-aventis U.s. Llc SARCLISA isatuximab INJECTION, SOLUTION, CONCENTRATE 761113 1 2020-03-02   Start Trial HYBRIGENICS S.A. (Paris, FR) 2039-12-05 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
McKinsey
Merck
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.